Aurobindo Pharma Ltd · NSE:AUROPHARMA
Aurobindo Pharma — Q3 FY2026 Earnings Presentation
21 slides from Aurobindo Pharma's earnings presentation, February 2026
Slide 1: Aurobindo Pharma Limited Earnings Presentation Q3FY26
Aurobindo Pharma Limited Earnings Presentation Q3FY26
Slide 2: Disclaimer
Disclaimer This presentation is provided for informational purposes only and does not constitute or form part of any offer or invitation to sell or issue, or any solicitation of any offer to purchase or subscribe for any interest in or securities of Aurobindo Pharma Limited, nor shall it, or any par
Slide 3: Table of Content
Table of Content 04 Q3FY26 Business & Financial Highlights 11 Update on Biosimilars 15 Financial Summary 13 18 Filings Snapshot 3
Slide 4: Q3FY26 Business & Financial Highlights
Q3FY26 Business & Financial Highlights 4
Slide 5: Key Financial Highlights of the Quarter
Key Financial Highlights of the Quarter Revenue EBITDA Net Profit Q3FY26 ₹ 8,646 Cr ₹ 1,773 Cr ₹ 910 Cr Q3FY25 ₹ 7,979 Cr ₹ 1,628 Cr ₹ 846 Cr Y-o-Y growth % 8.4% 9.0% 7.6% 55
Slide 6: Business Highlights – Q3FY26
Business Highlights – Q3FY26 Revenue of ₹8,646 crores with 8.4% growth YoY, driven by strong Europe performance coupled with stable US performance despite lower transient product sales Reported EBITDA of ₹1,773 crores with a margin of 20.5%, driven by stable gross margins and operating efficiencies
Slide 7: Quarterly Performance – Q3FY26
Quarterly Performance – Q3FY26 Revenue (Rs Crore) US Revenue excluding Puerto Rico (US$ Mn) 470 8,646 8,382 8,286 433 7,979 421 417 420 7,796 7,868 408 Q2FY25 Q3FY25 Q4FY25 Q1FY26 Q2FY26 Q3FY26 Q2FY25 Q3FY25 Q4FY25 Q1FY26 Q2FY26 Q3FY26 EBITDA (Rs Crore) Cash flows before dividend and buyback ($ Mn)
Slide 8: Consolidated Business Performance
Consolidated Business Performance ₹ Crores Q3FY26 Q3FY25 Y-o-Y (%) Q2FY26 Q-o-Q (%) USA 3,739 3,658 2.2% 3,638 2.8% Europe 2,703 2,121 27.4% 2,480 9.0% Growth Markets* 865 873 -0.9% 882 -1.9% ARV 376 307 22.4% 325 15.5% Total Formulations 7,683 6,960 10.4% 7,325 4.9% Beta-lactam 686 722 -4.9% 668 2.
Slide 9: US Formulations Business Performance Highlights (Excluding Puerto Rico)
US Formulations Business Performance Highlights (Excluding Puerto Rico) Revenue (US$ Mn) Commentary 440 433 • US revenue in Q3FY26 increased by 1% QoQ 420 420 417 accounting for 43.2% of consolidated revenue, 400 base business remained stable despite lower transient product sales 380 • The company h
Slide 10: Revenue Break-up by Business
Revenue Break-up by Business Europe (EUR Mn) Growth Markets (US$ Mn) ARV (US$ Mn) API (₹ Crore) 1,006 961 963 261 104 101 236 243 97 42 36 37 Q3FY25 Q2FY26 Q3FY26 Q3FY25 Q2FY26 Q3FY26 Q3FY25 Q2FY26 Q3FY26 Q3FY25 Q2FY26 Q3FY26 Growth Markets reported a YoY Europe business posted ARV business continue
Slide 11: Update on Biosimilars
Update on Biosimilars 11
Slide 12: CuraTeQ Biologics – Building a global biosimilars company
CuraTeQ Biologics – Building a global biosimilars company Approvals in Regulated Markets (RMs) The Opportunity Filings in RMs EEA - Zefylti, Dyrupeg, Dazublys ▪ Over 30 leading biologics, each generating 1–30 bn USD in revenues, are expected EMA - Bevqolva UK - Zefylti, Dyrupeg, Dazublys, and to los
Slide 13: BP16 and BP11 will sustain momentum of product filings in 2026
BP16 and BP11 will sustain momentum of product filings in 2026 Denosumab Omalizumab BP16 ▪ Denosumab (RANKL inhibitor) biosimilar candidate (BP16): Human ▪ A humanized IgG1κ monoclonal antibody that binds human IgE, used IgG2 monoclonal antibody targeting RANKL, aligned to reference to treat IgE-med
Slide 14: Strategic outlook and growth priorities
Strategic outlook and growth priorities ▪ Launch momentum in Europe : Bevqolva launched in the UK; Dazublys launched in Lithuania. Supplies initiated to additional countries including France and Germany for supporting upcoming launches ▪ Execution focus: Prioritizing launches across EEA markets whil
Slide 15: Financial Summary
Financial Summary 15
Slide 16: Summary Consolidated Profit & Loss Statement
Summary Consolidated Profit & Loss Statement Rs Cr Q3FY26 Q3FY25 YoY Chg. (%) Q2FY26 QoQ Chg. (%) Revenue from Operations 8,646 7,979 8.4% 8,286 4.3% Gross Profit 5,165 4,663 10.8% 4,947 4.4% Gross Margin 59.7% 58.4% 129 bps 59.7% 3 bps Overheads -3,391 -3,036 11.7% -3,269 3.8% EBITDA (before Forex
Slide 17: Debt Profile
Debt Profile Gross Debt (US$ Mn) Debt as on (INR Cr) Mar-22 Mar-23 Mar-24 Mar-25 Dec-25 Closing Rate (INR/USD) 75.793 82.170 83.405 85.475 89.875 966 963 930 884 843 786 Fx Loan restated in INR 2,223 4,638 3,994 5,883 5,818 Rupee Loan 150 224 2,324 2,065 1,249 232 228 182 185 117 99 Gross Debt 2,373
Slide 18: Filing Snapshot
Filing Snapshot 18
Slide 19: US ANDA Filings Snapshot as on 31st December 2025
US ANDA Filings Snapshot as on 31st December 2025 ANDA Filings Addressable Market Therapy ANDAs Size (US$ Bn)^^ CNS 161 33.3 Aurobindo (Excl. Specialty & 800 719 600 547 Specialty & Injectables 300 700 ARV 30 1.5 600 500 250 500 200 172 Injectables) 400 400 150 51.9 300 300 60 CVS 124 129 100 200 10
Slide 20: Global Regulatory Filing Details
Global Regulatory Filing Details As at As at As at As at As at As at As at As at As at As at Category Geography Mar 19 Mar 20 Mar 21 Mar 22 Mar 23 Mar 24 Mar 25 Jun 25 Sep 25 Dec 25 US* 541 586 639 727 774 830 861 865 876 879 Europe** 3,003 3,214 3,374 3,580 3,751 3,642 3,933 3,985 4,202 4,283 Formu
Slide 21: Thank You
Thank You For more information, contact: ir@aurobindo.com Investor Relations | Corporate Communications www.aurobindo.com +91 40 6672 1211 2121